Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Champions Oncology, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +3 vs. Q3 2024
- Shares held
- 5.72M
- −64.9K (−1.1%) vs. Q3 2024
- Total value
- $49.0M
- +$20.8M (+74.0%) vs. Q3 2024
- New holders
- 6
- 6 more added
- Sold out
- 3
- 3 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CSBR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 28 | $36.3M |
| Q1 2026 | 25 | $33.0M |
| Q4 2025 | 27 | $39.7M |
| Q3 2025 | 27 | $36.7M |
| Q2 2025 | 30 | $42.5M |
| Q1 2025 | 34 | $51.4M |
| Q4 2024 | 25 | $49.0M |
| Q3 2024 | 22 | $28.2M |
| Q2 2024 | 23 | $29.9M |
| Q1 2024 | 25 | $27.6M |
| Q4 2023 | 23 | $31.5M |
| Q3 2023 | 29 | $35.6M |
| Q2 2023 | 28 | $37.0M |
| Q1 2023 | 30 | $23.6M |
| Q4 2022 | 29 | $27.1M |
| Q3 2022 | 32 | $46.8M |
| Q2 2022 | 32 | $49.8M |
| Q1 2022 | 30 | $50.4M |
| Q4 2021 | 31 | $51.7M |
| Q3 2021 | 35 | $64.1M |
| Q2 2021 | 38 | $68.5M |
| Q1 2021 | 45 | $81.4M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Champions Oncology, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Battery Management Corp. | 2,421,673 | $20.8M | 2.66% | 00.0% | Unchanged |
| NEA Management Company, LLC | 1,713,720 | $14.7M | 0.83% | 00.0% | Unchanged |
| Tocqueville Asset Management L.P. | 608,915 | $5.22M | 0.08% | −96,299−13.7% | Reduced |
| Vanguard Group Inc | 307,002 | $2.63M | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 138,839 | $1.19M | 0.00% | +18,848+15.7% | Added |
| BlackRock, Inc. | 116,300 | $996.7K | 0.00% | +109+0.1% | Added |
| Morgan Stanley | 72,900 | $624.8K | 0.00% | +15,100+26.1% | Added |
| Geode Capital Management, LLC | 66,511 | $570.2K | 0.00% | +1,447+2.2% | Added |
| Northern Trust Corp | 53,994 | $462.7K | 0.00% | +12,923+31.5% | Added |
| HighTower Advisors, LLC | 39,308 | $336.9K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 30,697 | $261.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 26,749 | $229.2K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 26,553 | $227.6K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 25,272 | $216.6K | 0.00% | −36−0.1% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 12,252 | $105.0K | 0.00% | 00.0% | Unchanged |
| Mesirow Financial Investment Management, Inc. | 12,000 | $102.8K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 11,524 | $98.8K | 0.00% | +11,524 | New |
| Virtu Financial LLC | 11,051 | $95.0K | 0.01% | +11,051 | New |
| Millennium Management LLC | 10,941 | $93.8K | 0.00% | +178+1.7% | Added |
| Citadel Advisors LLC | 10,868 | $93.1K | 0.00% | +10,868 | New |
| Tower Research Capital LLC (TRC) | 1,640 | $14.1K | 0.00% | −913−35.8% | Reduced |
| Advisor Group Holdings, Inc. | 100 | $857 | 0.00% | +100 | New |
| JPMorgan Chase & Co | 11 | $94 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 4 | $34 | 0.00% | +4 | New |
| Capital Advisors, Ltd. LLC | 48 | $0 | 0.00% | +48 | New |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −48,413−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,279−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −113−100.0% | Sold out |